June 9, 2008 - Pharmalot -- The battle to win regulatory approval of the Dendreon prostate cancer vaccine has receded from the headlines, as a lawsuit, ad campaigns and protests failed to sway the FDA to move faster or cough up documents concerning its decision last year to override an advisory commitee that voted to endorse Provenge.
